
https://www.science.org/content/blog-post/crispr-latest-edition
# CRISPR: The Latest Edition (December 2017)

## 1. SUMMARY
The article reports on a breakthrough from the Salk Institute published in *Cell* that demonstrated a new CRISPR-based technique called "transcriptional editing" or "in vivo TGA" (transcriptional gene activation). Unlike classic CRISPR-Cas9 which cuts DNA double strands and risks leaving a trail of DNA damage, this method avoids double-strand breaks entirely by using shorter guide RNAs to keep the Cas9 enzyme from cutting, combined with transcriptional activators delivered via a single AAV viral vector.

The authors showed impressive proof-of-concept results in mouse models across multiple disease areas: inducing follistatin expression to increase muscle mass, activating IL-10 or Klotho to ameliorate kidney damage, turning liver cells into insulin-producing cells by activating Pdx1 to partially reverse Type 1 diabetes, and rescuing a Duchenne muscular dystrophy model by expressing Klotho or utrophin. The technique worked both in Cas9-transgenic mice and when delivering both components via viral vectors, including with nuclease-dead Cas9 variants. The authors presented this as a versatile tool for both basic biomedical research and potentially for treating human diseases through targeted epigenetic approaches.

## 2. HISTORY
The transcriptional activation approach described in this 2017 paper represented an important evolution of CRISPR technology, though the translation to approved therapies has been slower and more complex than initially hoped. In the subsequent seven years, this technology platform became known as CRISPRa (CRISPR activation) or CRISPRi (CRISPR interference/repression), distinguishing it from nuclease-based gene editing.

Research applications of CRISPRa/i expanded significantly, with the technology widely adopted for functional genomics screens, drug target validation, and basic research (as predicted). Scientists indeed found these tools valuable for studying gene function without permanent genome alterations. However, therapeutic applications faced substantial hurdles. The complexity of delivering multiple components (guide RNAs, transcriptional machinery, and sometimes Cas9 variants) in vivo remained challenging. AAV vectors, while useful, have limitations in cargo capacity and can trigger immune responses that limit repeat dosing.

While several preclinical studies demonstrated proof-of-concept for various diseases using CRISPRa/i approaches, no CRISPRa-based therapeutic has yet received FDA approval. A few companies pursued this direction, but most CRISPR therapeutic development shifted toward more straightforward nuclease-based editing approaches (for diseases where permanent DNA changes are acceptable) or base/prime editing. The field discovered that achieving predictable, sustained, and safe transcriptional modulation in human patients proved more difficult than in mouse models.

That said, the conceptual framework proved influential. The idea of modulating gene expression epigenetically rather than cutting DNA influenced the broader field and contributed to development of other epigenetic editing approaches. Some applications moved toward ex vivo use (manipulating cells outside the body) where delivery challenges are more manageable.

## 3. PREDICTIONS
**Predictions from the article:**
- The system would become widely adopted for in vivo biomedical research
- It would be developed for treating human diseases as a targeted epigenetic therapy
- Salk would need to decide whether to license the technology or start a company
- Other groups would extensively test and validate the system

**How predictions compared to reality:**

✓ **Widespread research adoption**: The prediction about extensive research use largely came true. CRISPRa/i systems became standard tools in molecular biology labs for functional genomics, with thousands of papers published using these approaches.

✓ **Tool for biomedical research**: The technology proved highly valuable for basic research, particularly for: drug target identification, functional screening, validating gene-disease associations, and studying gene networks without permanent alterations.

✗ **Rapid human therapeutic translation**: The article's optimistic timeline for human therapy did not materialize as quickly as suggested. As of 2024, no CRISPRa-based therapeutic has received regulatory approval, and the field discovered significant practical barriers to in vivo delivery and sustained expression.

✓ **Commercial development**: Multiple companies did pursue CRISPRa technology, including startups and established players, validating the prediction that commercial entities would engage with the approach.

**Specific technical aspects**: The authors' claims about avoiding double-strand breaks and using AAV delivery were accurate and important. However, the complexity of coordinated delivery of multiple components in humans proved more challenging than in mice, and safety concerns around long-term epigenetic modifications persisted.

The bigger picture is that while CRISPRa/i succeeded enormously as research tools (fulfilling one major promise), their therapeutic application remains largely in preclinical or early clinical stages, representing a more cautious and extended development pathway than the article suggested.

## 4. INTEREST
Rating: **7/10**
This article covers an important technological advancement that had significant impact on research methodology, though clinical translation progressed more slowly than anticipated. The interplay between scientific promise and practical development challenges makes it instructive.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20171208-crispr-latest-edition.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_